Genta - Waiting For Genasense To Make Sense Trading Markets (press release), CA - On December 3, the FDA is expected to decide whether Genasense injection merits approval for Chronic Lymphocytic Leukemia. Genasense, known generically as ...OTC:GNTA
Leukemia fight breaks barriers of culture, miles Akron Beacon Journal, OH - Nov 30, 2008 The troubles started innocently enough in May, when Lydia developed a throat infection she couldn't shake. An ear, nose and throat specialist recommended ...
The root, or stem, of the issue The University of Alabama Crimson White, AL - Stem cells are also used in bone marrow transplants for leukemia patients, in insulin production for diabetics and for joint repairs. ...
Downtown vs. the downturn NJ.com, NJ - Nov 30, 2008 She is hosting a benefit night for the Leukemia & Lymphoma society on Thursday, and instructed all of her staff to thank every shopper personally. ...
Soon, we have no bananas? Sarasota Herald-Tribune, FL - Women in Costa Rican banana-packing plants reportedly suffer double the average rates of leukemia and birth defects, and many male banana pickers become ...
New Cases of Cancer Decline in the US New York Times, United States - Nov 26, 2008 Alternatively, the decline may reflect inconsistent screening practices, causing some cancers that used to be detected to now go undiagnosed. ...
Styx River boy battles cancer Gulf Coast Newspapers, AL - Nov 30, 2008 Suspicious, Dalton?s pediatrician ordered some more tests, and in May of 2006, the Sirmons got the diagnosis. Dalton had ALL or acute lymphoblastic leukemia...
Potential New Drug Target For Chronic Leukemia Science Daily (press release) - Nov 24, 2008 He noted that a test for PDE7B might also potentially be used as a way to detect CLL, though this has yet to be proven. CLL, which usually strikes adults ...
How Childhood Leukemia Fights Back Science Now, DC - Nov 28, 2008 No one really knows, but for a long time researchers have thought that certain DNA changes in cancer cells may protect them from chemotherapy and allow them ...
Source: Google News
Recent News and Articles on the Keywords: leukemia + patient + 80,000 Related to the article below (Last Update: 8/7/2008)
Environment Becomes Heredity Miller-McCune.com, CA - Jul 17, 2008 Baylin points to the success of one drug, azacytidine, that delays the progression of a leukemia precursor, myelodysplasia, apparently by re-methylating ...
Source: Google News
Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro - JA Vilpo, T Koski, LM Vilpo - European Journal Of Haematology, 2000 - Blackwell Synergy ... in vitro at the time of sampling, for 35 patients with chronic lymphocytic leukemia Patient no. ... (B) The cultures were initiated with 0, 40 000, 80000, 120 000 ...
Rest thallium-201 myocardial perfusion imaging in a patient with leukaemic infiltration of the heart - A Cahid Civelek, JA Brinker, EE Camargo, JM Links, … - European Journal of Nuclear Medicine and Molecular Imaging, 1992 - Springer ... 4200/mm 3 and platelets of 80000/mm 3 ... replacement by myelo- monoblasts, and the patient
was transferred ... Johns Hopkins Oncology Center Adult Leukemia Service for ...
… effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia - L Bergmann, K Fenchel, B Jahn, PS Mitrou, D … - Annals of Oncology, 1993 - Eur Soc Med Oncology ... 13000 19000 18000 51000 46000 80000 12000 141000 ... standard regimens in these patient
groups are ... weekly chloranbucil treatment of chronic lymphocytic leukemia. ...
[PDF]A patient workflow management system built on guidelines - L Dazzi, C Fassino, R Saracco, S Quaglini, M … - Proc AMIA Annu Fall Symp, 1997 - amia.org ... GL to manage Acute Myeloid Leukemia (AML) in ...80000 ORPMN < 1000 PLT > 80000 ANDPMN >
1000 BM ...patient Requestresource NURSE RESOURCE MANAGER Professional-Nurse ... -
Reversing of chlorambucil resistance by ethacrynic acid in a B-CLL patient - M Petrini, A Conte, F Caracciolo, A Sabbatini, B … - British Journal of Haematology, 1993 - Blackwell Synergy ...80000 - ... same schedule was completely ineffective in another resistant patient affected
by ... expression in lymphocytes from chronic lymphocytic leukemia patients. ...
LEUKEMIA INDUCED BY THE ANTI-CD22 RECOMBINANT IMMUNOTOXIN BL22 RJ Kreitman, WH Wilson, I Pastan - Trends in Diphtheria Research, 2006 - books.google.com ... 36 36 N/A, not applicable,+ patient still in ... Complete Remissions of Purine
Analog-Resistant Hairy Cell Leukemia... ... 280 CO E120000 E. 55100000 _J (^ 80000, o ... -
A drug that has been used to treat thousands of leukemia patients may carry serious heart risks, say researchers.
Gleevec is designed to specifically target and prevent cancer cells from multiplying in patients with chronic myleogenous leukemia (CML) and some types of stomach cancer, but in laboratory tests, the drug has been shown to also destroy heart cells.
This finding is a big surprise," said Dr. Thomas Force, lead researcher and professor of medicine at Jefferson Medical College of Thomas Jefferson University, Pennsylvania.
In CML patients, a specific enzyme, Abelson tyrosine kinase (ABL) protein, becomes overactive and turns healthy blood cells cancerous, and they begin to multiply out of control. Gleevec works by targeting ABL and turning it off, so the cancer can no longer grow.
Researchers were prompted to study the heart risks of Gleevec after 10 patients with CML developed severe congestive heart failure while taking the drug. Researchers then looked at the impact of Gleevec on live mice and human heart cells. The results of the study are published in Nature Medicine.
In these tests, the study discovered that while ABL is to blame for CML, it is also necessary for the maintenance of healthy heart muscle. So, by turning off ABL, Gleevec can cause damage to the heart.
"While the cancer is treated effectively, there will be some percentage of patients who could experience significant left ventricular dysfunction and even heart failure from this," said Force.
Unfortunately, there seems to be no way of knowing which patients will have a cardiac problem while on Gleevec. But even with this warning, Force still thinks that this drug is an important tool in our cancer-fighting arsenal. As with all drugs, doctors need to be aware of the potential risks involved when writing a prescription.
"Gleevec is a wonderful drug, and patients with these diseases need to be on it," he said.
